This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment.

This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT.

This study investigated the long-term health-related quality of life (HQL) after colorectal cancer (CRC) surgery. Researchers suggested that overall long-term HQL was good, although some patients may need closer follow-up.

This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after surgery improved the overall survival of these patients.

This study investigated if vitamin D supplementation improves colorectal cancer (CRC) survival outcomes. Researchers suggested that vitamin D supplementation is associated with improved survival in CRC.

This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients.

This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes.

This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients.

This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients.

This study investigated the effects of bevacizumab (Avastin) combined with mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) treatment in RAS-positive advanced colorectal cancer (CRC). Researchers suggested that this treatment improved the treatment and survival outcomes of patients with CRC and liver metastasis (spread to the liver).